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Abstract
Rationale: Pulmonary fibrosis is a progressive disease with only few treatment options available at the moment.
Recently, the nucleoside uridine has been shown to exert anti-inflammatory effects in different animal models, e.g.
in acute lung injury or bronchial asthma.
Method: Therefore, we investigated the influence of uridine supplementation on inflammation and fibrosis in the
classical bleomycin model. Male C57BL/6 mice received an intratracheal injection of bleomycin on day 0 and were
treated intraperitoneally with uridine or vehicle. The degree of inflammation and fibrosis was assessed at different
time points.
Results: Uridine administration resulted in attenuated inflammation, as demonstrated by reduced leukocytes and
pro-inflammatory cytokines in the broncho-alveolar lavage (BAL) fluid. Furthermore, collagen deposition in the lung
interstitium was also reduced by uridine supplementation. Similar results were obtained in a model in which
animals received repeated intraperitoneal bleomycin injections. In addition uridine inhibited collagen and TGF-ß
synthesis by primary lung fibroblasts, the release of pro-inflammatory cytokines by human lung epithelial cells, as
well as the production of reactive oxygen species by human neutrophils.
Conclusion: In summary, we were able to show that uridine has potent anti-inflammatory and anti-fibrotic properties.
As uridine supplementation has been shown to be well tolerated and safe in humans, this might be a new therapeutic
approach for the treatment of fibrotic lung diseases.
Background
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown
origin characterized by progressive loss in lung function
leading to respiratory failure with currently no effective
treatment options available and therefore a poor prognosis.
The pathophysiology of IPF is not fully understood yet.
However, injury of alveolar epithelial cells (AECs) par-
alleled by oxidative stress leading to abnormal activa-
tion of fibroblasts is considered to be crucial in this
context. The formation of fibroblast and myofibroblast
foci via the proliferation of lung fibroblasts, the recruitment
of circulating fibrocytes, and epithelial to mesenchymal
transition hereby depends on mediators secreted by acti-
vated AECs. In summary, these processes result in excessive
deposition of collagen, fibronectin and other components
of the extracellular matrix in the lung parenchyma [1–3].
Besides their well-characterized role in cell metabol-
ism, the involvement of different nucleosides in particu-
lar adenosine in different inflammatory disorders has
been demonstrated extensively. Adenosine-induced over-
production of IL-13 results in pulmonary fibrosis, re-
spiratory failure and death in a transgenic mouse model
[4]. Inosine in contrast has been found to be protective
in animal models of acute lung injury or bronchial asthma
in an adenosine receptor-dependent manner [5, 6]. In con-
trast no receptor has been identified for the nucleoside
uridin so far which has also been demonstrated to have
anti-inflammatory properties [7]. Recently we were able to
show that the exogenous application of uridine results
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in decreased allergic airway inflammation in both
OVA- and house dust mite induced asthma. Though
the mechanisms behind these findings could not be
fully resolved an effect on lung epithelial cells could be
shown [8]. Additionally, uridine is a potent inhibitor of
leucocyte adhesion [9]. Interestingly, oral uridine supple-
mentation is a safe, well tolerated and efficacious treat-
ment to reduce mitochondrial toxicity caused by highly
active antiretroviral therapy (HAART) in humans [10, 11].
In this study we investigated therapeutic properties of
uridine in the classical animal model of bleomycin-
induced lung injury and fibrosis.
Material and methods
Animals
C57Bl/6 mice, were bred at the animal facility at the
University of Freiburg. All experiments were performed ac-
cording to institutional guidelines of the local animal ethics
committee (Regierungspräsidium Freiburg).
Bleomycin model of pulmonary fibrosis (intratracheal model)
Male C57BL/6 animals were anaesthetized by i.p. keta-
mine/xylazine administration and received an intratracheal
(i.t.) injection of bleomycin (80 μl, 1 mg/ml) or vehicle
(saline) as a negative control. Animals were treated with
uridine (80 μl, 24 μg/ml; Sigma Aldrich, Germany) or ve-
hicle at the indicated time points. Mice were sacrificed at
different time points (see results section) via i. p. injection
of thiopental. BAL was performed with 3 × 1ml of Ca2+ and
Mg2+ free PBS (Gibco, Paisley, UK) supplemented with 0.1
mM sodium EDTA (Sigma Aldrich, Germany), followed by
lung resection and storage in OCT freezing medium. BAL
cells were counted, differential cell counts were done by
FACS analysis, as described previously [12]. Frozen lung
sections were stained with hematoxylin and eosin for histo-
logical analysis.
Bleomycin model of pulmonary fibrosis
(intraperitoneal model)
Male C57BL/6 animals received i.p. injections of bleo-
mycin (140 μl, 6 mg/ml) or vehicle (saline) as a negative
control twice a week over 4 weeks. Starting from day 14
on animals were treated intraperitoneally with uridine
(200 μl, 2,4 mg/ml) or vehicle 3 times a week. On day 30
animals were killed and BAL was performed and ana-
lysed as described above. Frozen lung sections were
stained with hematoxylin and eosin for histological
analysis.
Mediator measurements in BALF
BALF cytokine contents were determined by ELISA (R&D
Systems, Minneapolis, USA), as described by the manufac-
turer. BALF collagen content was measured by Sircol assay
(Biocolor, Carrickfergus, UK).
Collagen quantification in histological lung slides
Frozen lung sections were incubated in picrosirius red solu-
tion (0,2 gr of Picosirius Red diluted in 100 ml of 1,2 % pic-
ric acid, both Sigma-Aldrich), for one hour. After washing
with water, tissue sections were stained with hematoxylin
for 5–10 s. Slides were washed with running tap water and
dehydrated in 70 %, 90 % and absolute ethanol, followed by
xylene. Entellan (Merck) was used to mount the coverslip.
Images were obtained using Axio Lab.A1 microscope
(Zeiss) with 200× magnification and AxioCam ICc1 (Zeiss).
Collagen quantification was made with ImageJ.
Cell culture
A549 cells were grown in RPMI1640-Medium (Gibco,
Paisley, UK) containing 10 % fetal calf serum (FCS;
Biochrom, Berlin, Germany) and 1 % penicillin/strepto-
mycin (P/S; Gibco, Paisley, UK) in cell culture flasks
(BD Falcon, Bedford, MA) at 37 °C, 5 % CO2, and 100 %
humidity. For subculture cells were trypsinized and seeded
into 24-well tissue culture plates at a density of 2 × 105 cells/
well. After 2 h, medium was changed and cells were stimu-
lated as indicated. After additional 8 h, cell supernatants
were collected and analyzed by ELISA.
For the isolation of primary lung fibroblasts lungs of
C57Bl/6 mice were excised and cut in small pieces, followed
by digestion with collagenase. Single cell suspensions were
obtained by passing through a cell strainer. Cells were
grown in RPMI1640-Medium (Gibco, Paisley, UK) (supple-
mented 10 % FCS and 1 % P/S) in cell culture flasks (BD
Falcon, Bedford, MA) at 37 °C, 5 % CO2 in a humidified at-
mosphere. Medium was changed every 2 or 3 days. Cells
were trypsinized after 14 days and used for experiments.
Purify of isolated cells was assessed by microscopy. The cells
were seeded into 6-well tissue culture plates at a density of
0,5 × 106 cells/well. After 24h, medium was changed and
cells were stimulated with Bleomycin (1 μg/ml) ± uridine.
After 24 h, total RNA of these cells was isolated with
Qiazol (QIAGEN GmbH, Hilden, Germany) according
to the manufacturer’s protocol.
Isolation of human neutrophils and measurement of reactive
oxygen species (ROS)
Neutrophils from healthy volunteers were isolated from ven-
ous blood using a Pancoll gradient (PAN-Biotech GmbH,
Aidenbach, Germany) as described previously [13]. Resulting
neutrophils were resuspended in PBS. Neutrophils were
seeded in 96-well plates (1 × 105/well), in RPMI1640
medium supplemented with 10 % FCS and penicillin/
streptomycin, and incubated at 37 °C, 5 % CO2 in a hu-
midified atmosphere. Neutrophils were preincubated
with uridine (10−5 mol/l) or vehicle for 15 min, then
50 μl of lucigenin (2 mg/ml) was added. Finally, 10 μl of
Bleomycin (1 μg/ml) were added to the cells and the stimu-
lated generation of ROS was measured by a computerized
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chemoluminometer at 37 °C (Berthold Technologies
LP96V, Germany).
Quantitative PCR
Quantitative PCR was performed on LightCyler 480
(Roche) using the fast-blue + UNG kit (Eurogentec).
Collagen, TGF-β and ß2-microglobulin primers/probes
were designed using Beacon Designer v 7.50 (Premier
Biosoft). Percent reference gene (RG) values for the gene
of interest (GOI) were calculated using the formula:
% RG = 100 × 2(−ΔCt). Cumulative standard deviations
were calculated using the formula: SD = 100 × 2(−ΔCt) ×
((ln2 × SDRG)2 + (ln2 × SDGOI)2)1/2 [12].
Statistical analysis
If not stated otherwise, groups were compared using anova,
followed by Bonferroni comparison test. Probability values
of p < 0.05 were regarded as significant.
Results
Uridine supplementation decreases inflammation in the
early phase after intratracheal bleomycin administration
To investigate the influence of uridine supplementa-
tion on the course of fibrotic lung disease we used
the well-established animal model of bleomycin induced
lung injury/fibrosis. In the prophylactic protocol mice re-
ceived an intratracheal injection of bleomycin or vehicle on
day 0. Animals were treated intraperitoneally with uridine
or vehicle after 6 h, on day 5 and on day 10 following bleo-
mycin administration. Animals were sacrificed on day 7
and day 14 and assessed for inflammation and fibrosis.
Treatment with uridine resulted in decreased inflammation,
as shown by reduced inflammatory cells in the broncho al-
veolar lavage (BAL) fluid (Fig. 1a). This was paralleled by
decreased BAL fluid cytokine levels and by attenuated
inflammation on histological lung sections (Fig. 1b, c). In
addition, the collagen content in the BAL fluid was lower
in the animals treated with uridine (Fig. 1d).
Uridine supplementation decreases inflammation and
fibrosis in the late phase after intratracheal bleomycin
administration
As uridine was able to decrease inflammation and fibro-
sis when administered early after bleomycin we next
questioned whether uridine administration is also pro-
tective during the fibrotic phase. Therefore, bleomycin
or vehicle was injected intratracheally on day 0. Starting
from day 14 mice were treated 3 times a week with either
uridine or vehicle. The degree of inflammation and fibrosis
was determined on day 30. As shown in Fig. 2a, uridine
treatment significantly reduced total BAL cell count and
the number of macrophages and lymphocytes. Additionally,
the concentration of pro-inflammatory and pro-fibrotic
cytokines was lower in the BAL fluid derived from uridine-
treated animals (Fig. 2b). Furthermore, we observed re-
duced collagen deposition in the airspaces and decreased
collagen levels in the BAL fluid (Fig. 2c, d).
Uridine supplementation inhibits inflammation and fibrosis
following chronic bleomycin administration
In contrast to IPF in humans, pulmonary fibrosis after a
single intratracheal bleomycin administration is known to
be self-limiting. Hence, another model in which mice were
repeatedly exposed to intraperitoneal bleomycin was used.
This model is characterized by long lasting fibrosis and
subpleural scaring, a pattern similar to usual interstitial
pneumonia (UIP) in humans [14]. Therefore, animals re-
ceived intraperitoneal bleomycin injections twice a week
over 4 weeks. Treatment with uridine which was started at
day 15 was associated with a strong reduction in inflamma-
tion as demonstrated by reduced inflammatory cells and
pro-inflammatory cytokines in the BAL fluid (Fig. 3a, b).
Moreover, histological analysis showed decreased tissue fi-
brosis paralleled by lower collagen contents in the BAL
fluid of uridine treated animals (Fig. 3c, d).
Uridine inhibits the release of pro-inflammatory mediators
by human lung epithelial cells
Alveolar epithelial cells are known to play a pivotal role in
the pathogenesis of fibrotic lung diseases [1]. In pursuit of
the mechanisms behind our findings we investigated the ef-
fects of uridine on the production of the pro-inflammatory
cytokines IL-6 and IL-8 by A549 cells, a cell line resembling
human alveolar epithelial cells type 2. As shown in Fig. 4,
uridine was able to suppress the bleomycin induced release
of both IL-6 and IL-8 in a dose dependent manner.
Uridine inhibits collagen and TGF-β production by primary
lung fibroblasts
Excessive production and deposition of extracellular matrix
components by lung fibroblasts is crucial for the develop-
ment of pulmonary fibrosis. In addition fibroblasts interact
with inflammatory and lung structural cells and are capable
of releasing different cytokines and growth factors [2]. As
demonstrated in Fig. 5, uridine decreased collagen and
TGF-ß mRNA synthesis by primary lung fibroblasts.
Uridine inhibits production of reactive oxygen species by
human neutrophils
The importance of oxidative stress in the pathophysiology
of pulmonary fibrosis has been demonstrated extensively
[2]. Thus we sought to determine whether uridine can
influence the production of reactive oxygen species by
human neutrophils. As shown in Fig. 6, exposure to
bleomycin resulted in transient ROS production. How-
ever, pre-treatment with uridine significantly inhibited
ROS production by neutrophils.
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Fig. 1 (See legend on next page.)
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Fig. 2 Uridine supplementation decreases inflammation and fibrosis in the late phase after intratracheal bleomycin administration. Animals were treated
with i. t. bleomycin on day 0. Uridine or vehicle was administered three times a week starting from day 14. Animals were assessed for inflammation and
fibrosis at day 30. a BALF differential cell counts. b BALF cytokine levels. c HE stainings of lung sections. d BALF collagen content. e Collagen content on
histological lung slides. Data are means ± SEM, n= 4–6 mice per group. *p < 0.05; **p< 0.01; ***p< 0.001; ****p< 0,0001. The experiment was repeated
twice with similar results
(See figure on previous page.)
Fig. 1 Uridine supplementation decreases inflammation in the early phase after intratracheal bleomycin administration. Animals were treated
with i. t. bleomycin on day 0. Uridine or vehicle was administered after 6 h, at day 5 and at day 10. Animals were assessed for inflammation and
fibrosis at day 7 and day 14. a BALF differential cell counts. b BALF cytokine levels. c HE stainings of lung sections. d BALF collagen content.
e Collagen content on histological lung slides. Data are means ± SEM, n = 4–6 mice per group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0,0001.
The experiment was repeated twice with similar results
Cicko et al. Respiratory Research  (2015) 16:105 Page 5 of 10
Discussion
The involvement of the nucleoside adenosine in the
pathogenesis of inflammatory lung disorders, including
pulmonary fibrosis has been studied extensively [4, 15, 16].
Recently, we were able to demonstrate that local admin-
istration of uridine inhibited the cardinal features of
Fig. 3 Uridine supplementation inhibits inflammation and fibrosis following chronic bleomycin administration. Animals were treated with i. p. bleomycin
twice a week over a time period of 4 weeks. Starting from day 14 on animals received either uridine or vehicle for 3 times a week. Animals were assessed
for inflammation and fibrosis at day 30. a BALF differential cell counts. b BALF cytokine levels. c HE stainings of lung sections. d BALF collagen content.
e Collagen content on histological lung slides. Data are means ± SEM, n= 4–9 mice per group. *p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0,0001. The
experiment was repeated once with similar results
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bronchial asthma [8]. In this study we investigated
whether uridine supplementation can also influence the
course of fibrotic lung disease.
In an acute model of bleomycin induced lung injury in-
traperitoneal treatment with uridine resulted in decreased
inflammation and collagen deposition. These results are in
line with previous studies showing that uridine adminis-
tration is protective in Sephadex- or allergen-induced lung
inflammation [7, 8, 17]. However, beyond dampening in-
flammation following acute bleomycin administration uri-
dine was also able to suppress tissue fibrosis at later time
points. Furthermore, fibrotic changes were also reduced
by uridine when bleomycin was administered repeatedly.
This animal model is characterized by longer lasting fibrosis
with subpleural predominance. Hence it is supposed to be
closer to idiopathic pulmonary fibrosis in humans than the
acute model [14]. To our best knowledge this is the first
study showing that uridine has both anti-inflammatory and
anti-fibrotic properties.
A receptor specific for uridine has not been identified,
yet. Consequently, it has been hypothesized that uridine
might exert its effects indirectly via the generation of
UDP and UTP being able to bind to the purinergic re-
ceptors P2Y2, P2Y4, and P2Y6. However, both P2Y2 and
P2Y6 receptor subtypes have actually been demonstrated
to mediate pro-inflammatory effects in bronchial asthma
or chronic obstructive pulmonary disease [12, 18, 19]. An-
other possibility might be the interaction of uridine with
adenosine receptors. In accordance with this a previous
study demonstrated that uridine can actually activate A1
receptors [20]. Though there is evidence that A1 receptors
exhibit both pro- and anti-inflammatory activities, most
studies suggest that the activation of A1 receptors is in
summary pro-inflammatory [21, 22]. Moreover, deficiency
Fig. 4 Uridine inhibits the release of pro-inflammatory mediators by human lung epithelial cells. A549 cells were stimulated with bleomycin (1 μg/ml)
± uridine. After an incubation period of 24 h levels of IL-6 and IL-8 in cell culture supernatants were determined by ELISA. Data are means ± SEM, n = 3.




















Fig. 5 Uridine inhibits collagen and TGF-β production by primary lung fibroblasts. Fibroblasts were stimulated as indicated for 8 h, total RNA was
isolated. The mRNA specific for collagen and TGF-β was quantified as described. Data are means ± SEM, n = 3. *p < 0.05; **p < 0.01; ***p < 0.001
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in adenosine deaminase resulting in increased pulmonary
adenosine levels actually leads to a fibrotic lung disease.
Additionally, in a previous study we were able to demon-
strate that the anti-inflammatory effects of uridine on lung
epithelial cells were not dependent on adenosine receptors
[8]. Therefore, taken together the anti-inflammatory and
anti-fibrotic effects of uridine are most likely independent
of adenosine receptors.
The subsequent release of pro-inflammatory and pro-
fibrotic cytokines/chemokines after epithelial cell injury
is a crucial step in the pathogenesis of fibrotic lung dis-
eases [1]. In this study we were able to demonstrate that
when co-administered with bleomycin uridin inhibited
the release of the pro-inflammatory cytokines IL-6 and IL-8
by human alveolar epithelial cells. The latter one is consid-
ered as the key chemokine for the recruitment and acti-
vation of neutrophils [23]. Interestingly, an association
between a high BAL fluid neutrophil count and a poor
prognosis in IPF has been found [24]. Apart from in-
flammation IL-8 has been identified as a pro-angiogenic
factor in the context of idiopathic pulmonary fibrosis [25].
IL-6 is a pleiotropic cytokine whose importance in various
lung disorders including pulmonary fibrosis has been dem-
onstrated extensively [15, 26]. Hence, uridine might influ-
ence the course of fibrotic lung disease by altered cytokine
secretion of epithelial cells. However, in vivo altered
cytokine secretion after uridine administration might
not be limited exclusively to airway epithelial cells and
indirect effects of uridine might also be of importance.
In a line with these findings, uridine was also able to
decrease TGF-ß and collagen synthesis by primary
lung fibroblasts. The production and deposition of
collagen and other extracellular matrix components is a
characteristic feature of pulmonary fibrosis. In this
context TGF-ß has been identified as an important
growth factor, mediating e.g. epithelial to mesenchymal
transition [27].
Though the exact role of oxygen radicals in the patho-
physiology of IPF remains controversial increased markers
of oxidative stress have been found in IPF patients [28].
Thus decreased production of reactive oxygen species
might contribute to reduced pulmonary inflammation
and fibrosis in uridine treated animals.
As mentioned earlier in this manuscript treatment with
uridine has been shown to abrogate mitochondrial toxicity
induced by anti-retroviral therapy in patients infected with
HIV [10, 11]. Recently, mitochondrial dysfunction has
gained attention as a mechanism contributing to epithelial
cell injury and the progression of pulmonary fibrosis
[29, 30]. Hence, uridine supplementation might lead to
an improved mitochondrial function thereby limiting
pulmonary inflammation and fibrosis.
Nucleosides are rapidly metabolized in the extracellular
space. Adenosine, e.g. is characterized by an extremely
short half-life when administered intravenously [31].
Hence the pharmacokinetic characteristics of uridine have
to be taken in account in this context. However, previous
studies were able to demonstrate that the half-life of uridine
in plasma is considerably higher compared to adenosine
[32, 33]. Accordingly, uridine plasma levels after intraperi-
toneal administration appear to be high enough to exert
anti-inflammatory and anti-fibrotic effects.
Fig. 6 Uridine inhibits production of reactive oxygen species by human neutrophils. Neutrophils were stimulated as indicated and lucigenin-dependent
chemiluminescence was measured. a Time courses upon stimulation with vehicle, bleomycin, and bleomycin + uridine. One representative
out of 8 experiments is shown. b Maximal chemoluminescence after stimulation with vehicle, bleomycin, and bleomycin + uridine. Data are
means ± SEM, n = 7. *p < 0.05; **p < 0.01; ***p < 0.001; ****p< 0,0001
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In summary we demonstrated that uridine inhibits in-
flammation and fibrosis in bleomycin induced lung injury.
As a receptor specific for uridine has not been identified
yet, the exact mechanisms behind these findings are not
completely understood at the moment. Nevertheless,
uridine inhibited the production of collagen and pro-
inflamamtory/fibrotic cytokines by alveolar epithelial
cells and lung fibroblasts, as well as the release of re-
active oxygen species by activated neutrophils. Inter-
estingly, uridine supplementation has been found to be
safe and well tolerated in humans [10, 11]. Therefore,
further studies investigating the impact of uridine
administration on the course of fibrotic lung diseases
in humans would be of great interest.
Conclusions
Uridine which can be safely administered in humans is
a potent inhibitor of bleomycin-induced pulmonary
inflammation and fibrosis. Consecutively, though further
research is still needed, this might be a new approach
for the treatment of fibrotic lung diseases in humans.
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